A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
Status:
Completed
Trial end date:
2020-02-20
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of aripiprazole
long-acting injectable (LAI) (420 mg) following deltoid or gluteal muscle administration in
adult subjects with schizophrenia or bipolar I disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.